Gastric Cancer
Conditions
Brief summary
There are more than 75% of patients with gastric cancer who are diagnosed in advanced stage in Vietnam, most of cases in T4a. The purpose of this study was to compare short- and long- term outcomes of open and laparoscopic distal gastrectomy for gastric adenocarcinoma in surgical T4A stage.
Detailed description
Gastric cancer is one of the most common cancers in Vietnam . Despite recent advances in multimodality treatment and targeted therapy, surgery remains the first option of treament for this disease. For resectable gastric cancer, complete removal of macroscopic and microscopic lesions and/or combined resections and also regional or extended lymphadenectomy should represent worldwide now. Laparoscopic gastrectomy for locally advanced gastric cancer AGC have commonly used for treatment of AGC, especially in Japan, Korea and China. However, the real role of laparoscop for treament of (AGC) is still controversial in term of technical feasibility, safety and oncologic aspect for T4a stage. Paragastric inflammatory strands may occur in T4a tumor so that laparoscopic technique is difficult to radically perform. Peritoneal seeding of malignant cells, intra- and postoperative complications, trocarts metastasis may risk during procedures. Despite, some studies have demonstrated the safety and the short-term benefits of LG for T4a gastric cancer, the number of these studies and sample sizes have been still inadequate to give good evidence for applying it. and long-term oncologic outcomes There are more than 75% of patients with gastric cancer who are diagnosed in advanced stage in Vietnam, most of cases in T4a. The purpose of this study was to compare short- and long- term outcomes of open and laparoscopic distal gastrectomy for gastric adenocarcinoma in surgical T4A stage.
Interventions
PROCEDURELaparoscopic distal gastrectomy
Distal gastrectomy and standard D2 lymphadenectomy
Sponsors
University Medical Center Ho Chi Minh City (UMC)
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* patients with histologically confirmed adenocarcinoma of the stomach, surgical staging of sT4aN0-3M0 according to the 7th edition of the American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) staging system
Exclusion criteria
* intraoperatively detected bulky lymph nodes * inadequate lymphadenectomy (D0, D1, D1+) * macroscopic residual tumor (R2) * an American Society of Anaesthesiology (ASA) score of \> IV * concurrent cancer or history of previous other cancers * previous gastrectomy * neoadjuvant chemotherapy * complications such as bleeding or perforation required emergency gastrectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 5 year overall survival by Kaplan Mayer | 5 year after surgery | The percentage of people in this study who are alive five years after surgery. |
| 5 year disease-free survival by Kaplan Mayer | 5 year after surgery | The percentage of people in this study who are alive without recurrence/metastasis five years after surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1 year disease-free survival by Kaplan Mayer | 1 year after surgery | The percentage of people in this study who are alive without recurrence/metastasis one years after surgery. |
| 3 year disease-free survival by Kaplan Mayer | 3 year after surgery | The percentage of people in this study who are alive without recurrence/metastasis one years after surgery. |
| operative morbidity | 30 days after surgery | The overall rate of postoperative complications |
| operative time | intraoperative | The duration of a surgical procedure in minutes. |
| 1 year overall survival by Kaplan Mayer | 1 year after surgery | The percentage of people in this study who are alive one years after surgery. |
| time to flatus | 30 days after surgery or until mortality ] | Number of days from date of surgery until date of flatus |
| Postoperative hospital length of stay | 30 days after surgery or until mortality | Number of days from date of surgery until date of discharge or mortality |
| The percentage of complications with Clavien-Dindo | 30 days after surgery | The percentage of complication grade by Clavien-Dindo classification |
| The percentage of pattern of recurrence/metastasis | 5 year after surgery | The percentage of pattern of recurrence/metastasis during follow up period |
| operative blood loss | intraoperative | The amount of blood lost during procedure |
| 3 year overall survival by Kaplan Mayer | 3 year after surgery | The percentage of people in this study who are alive one years after surgery. |
Countries
Vietnam
Outcome results
None listed